>
Shadowy Forces Behind JD Vance's Rise and Grooming as MAGA Successor
Who Is Paying Alberta, Canada, Premier Danielle Smith if Not Big Pharma?
RFK Jr. kills off $122M in grants to LGBT and diversity causes in sweeping action
Trump Unveils Another $825M Arms Sale To Ukraine, While Talking Peace
NVIDIA just announced the T5000 robot brain microprocessor that can power TERMINATORS
Two-story family home was 3D-printed in just 18 hours
This Hypersonic Space Plane Will Fly From London to N.Y.C. in an Hour
Magnetic Fields Reshape the Movement of Sound Waves in a Stunning Discovery
There are studies that have shown that there is a peptide that can completely regenerate nerves
Swedish startup unveils Starlink alternative - that Musk can't switch off
Video Games At 30,000 Feet? Starlink's Airline Rollout Is Making It Reality
Automating Pregnancy through Robot Surrogates
Grok 4 Vending Machine Win, Stealth Grok 4 coding Leading to Possible AGI with Grok 5
Known as "histotripsy," the method and machinery have already been tested successfully in animals and humans, and has just been approved for use by the FDA.
HistoSonics is a company founded in 2009 to create an ultrasound device that both screens for tumors and administers histotripsy. It was born from the efforts of scientists at the University of Michigan who co-founded the firm.
"Histotripsy is an exciting new technology that, although it is in early stages of clinical use, may provide a noninvasive treatment option for patients with liver cancer. Hopefully it can be combined with systemic therapies for a synergistic therapeutic effect," said Mishal Mendiratta-Lala, professor of radiology with Michigan Medicine.
Mendiratta-Lala was the principal investigator of an FDA human trial started in 2021 which confirmed that HistoSonic's device, called Edison, can destroy cancer tumors.